Oncotarget

Research Papers:

Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment

Cheng-Ming Hsu, Pai-Mei Lin, Jan-Gowth Chang, Hsin-Ching Lin, Shau-Hsuan Li, Sheng-Fung Lin and Ming-Yu Yang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:74348-74358. https://doi.org/10.18632/oncotarget.20637

Metrics: PDF 838 views  |   HTML 1413 views  |   ?  


Abstract

Cheng-Ming Hsu1,2,3, Pai-Mei Lin4, Jan-Gowth Chang5,6,7, Hsin-Ching Lin2, Shau-Hsuan Li8, Sheng-Fung Lin9,10 and Ming-Yu Yang2,3

1Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Chiayi, Taiwan

2Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

3Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan

4Department of Nursing, I-Shou University, Kaohsiung, Taiwan

5Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan

6College of Medicine, China Medical University, Taichung, Taiwan

7Epigenome Research Center, China Medical University Hospital, Taichung, Taiwan

8Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

9Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

10Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence to:

Ming-Yu Yang, email: yangmy@mail.cgu.edu.tw

Sheng-Fung Lin, email: shlin@cc.kmu.edu.tw

Keywords: SLC22A3, cancer therapy, cisplatin, survival, head and neck squamous cell carcinoma

Received: June 16, 2017     Accepted: August 17, 2017     Published: September 04, 2017

ABSTRACT

Solute carrier family 22 member 3 (SLC22A3), also called organic cation transporter 3 (OCT3), is responsible for organic cation transport, which can eliminate many endogenous small organic cations, drugs, and toxins. This study investigated whether SLC22A3 expression is related to cisplatin uptake and the survival of patients with head and neck squamous cell carcinoma (HNSCC). Using immunohistochemical staining and digital image analysis, SLC22A3 expression was examined in 42 HNSCC patients who were postoperatively treated with or without adjuvant chemotherapy. SLC22A3-overexpressing SCC-4 cells and SLC22A3-knocked down SCC-25 cells were used to investigate the function of SLC22A3 in cisplatin uptake. We found that patients with higher SLC22A3 expression had longer survival times than those with lower SLC22A3 expression (p = 0.051). Moreover, among advanced T-stage patients receiving adjuvant cisplatin therapy, those with higher SLC22A3 expression had longer survival times than those with lower SLC22A3 expression (p = 0.006). An in vitro study demonstrated that SCC-25 cells with upregulated SLC22A3 expression were more sensitive to cisplatin than were SCC-4 cells with downregulated SLC22A3 expression. An increased uptake of cisplatin and an enhanced cytotoxic effect were observed in SLC22A3-overexpressing SCC-4 cells, and decreased uptake was found in SLC22A3-knocked down SCC-25 cells. Our results demonstrated that upregulated SLC22A3 expression can increase the cisplatin uptake and subsequently improve the survival of patients with HNSCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20637